KR20230127292A - 항-cd73 항체의 제제 - Google Patents
항-cd73 항체의 제제 Download PDFInfo
- Publication number
- KR20230127292A KR20230127292A KR1020237025806A KR20237025806A KR20230127292A KR 20230127292 A KR20230127292 A KR 20230127292A KR 1020237025806 A KR1020237025806 A KR 1020237025806A KR 20237025806 A KR20237025806 A KR 20237025806A KR 20230127292 A KR20230127292 A KR 20230127292A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- cancer
- composition
- val
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020141601 | 2020-12-30 | ||
| CNPCT/CN2020/141601 | 2020-12-30 | ||
| PCT/CN2021/092485 WO2022142053A1 (en) | 2020-12-30 | 2021-05-08 | Formulations of anti-cd73 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230127292A true KR20230127292A (ko) | 2023-08-31 |
Family
ID=82258959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237025806A Pending KR20230127292A (ko) | 2020-12-30 | 2021-05-08 | 항-cd73 항체의 제제 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240101698A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4271410A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024505128A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230127292A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116615458A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021415180A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203441A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022142053A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025021098A1 (zh) * | 2023-07-24 | 2025-01-30 | 石药集团巨石生物制药有限公司 | 重组人源化抗cd73单克隆抗体的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2578131A1 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
| WO2010056804A1 (en) * | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| CN102512384B (zh) * | 2011-12-29 | 2014-11-26 | 嘉和生物药业有限公司 | 一种冻干剂型蛋白组合物及其制备方法 |
| CN108025072A (zh) * | 2015-09-22 | 2018-05-11 | 辉瑞公司 | 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂 |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン,エルエルシー | 抗pd−l1および抗ctla−4抗体の共製剤を含む組成物 |
| CA3045376C (en) * | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| US20210054079A1 (en) * | 2018-04-25 | 2021-02-25 | Medimmune Limited | Formulations of human anti-pd-li antibodies |
| CN112041348B (zh) * | 2018-07-25 | 2023-09-22 | 天境生物科技(上海)有限公司 | 抗cd73抗pd-l1双特异性抗体 |
| SG11202105152YA (en) * | 2018-11-30 | 2021-06-29 | Abl Bio Inc | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
-
2021
- 2021-05-08 JP JP2023540516A patent/JP2024505128A/ja active Pending
- 2021-05-08 CA CA3203441A patent/CA3203441A1/en active Pending
- 2021-05-08 AU AU2021415180A patent/AU2021415180A1/en active Pending
- 2021-05-08 KR KR1020237025806A patent/KR20230127292A/ko active Pending
- 2021-05-08 WO PCT/CN2021/092485 patent/WO2022142053A1/en not_active Ceased
- 2021-05-08 CN CN202180079028.7A patent/CN116615458A/zh active Pending
- 2021-05-08 US US18/270,472 patent/US20240101698A1/en active Pending
- 2021-05-08 EP EP21912814.7A patent/EP4271410A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116615458A (zh) | 2023-08-18 |
| EP4271410A1 (en) | 2023-11-08 |
| WO2022142053A1 (en) | 2022-07-07 |
| AU2021415180A1 (en) | 2023-07-06 |
| CA3203441A1 (en) | 2022-07-07 |
| EP4271410A4 (en) | 2025-08-13 |
| US20240101698A1 (en) | 2024-03-28 |
| JP2024505128A (ja) | 2024-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7653465B2 (ja) | 単独およびプログラム死受容体1(pd-1)抗体と組み合わされた抗ctla4抗体の安定な製剤、ならびにその使用方法 | |
| US20230321234A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| KR102770786B1 (ko) | 항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법 | |
| TWI880888B (zh) | 抗體-藥物結合物之製劑及其冷凍乾燥方法 | |
| US20220387314A1 (en) | Albumin-pd-1 paclitaxel nanoparticle complex compositions and methods of making and using the same | |
| US20080166346A1 (en) | Lyophilised Preparation Comprising Antibodies Against The EFG Receptor | |
| KR20210089215A (ko) | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 | |
| CN110913906A (zh) | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 | |
| EP3991745A1 (en) | Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof | |
| JP7805289B2 (ja) | 抗コネキシン抗体製剤 | |
| WO2022128716A1 (en) | Pharmaceutical composition comprising a bispecific anti-muc1/egfr antibody-drug conjugate | |
| CA3252354A1 (en) | Pharmaceutical composition containing an anti-nectin-4 antibody conjugate and its use | |
| KR100700963B1 (ko) | 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제 | |
| TW202511293A (zh) | 包含抗ccr8抗體的製劑及其用途 | |
| KR20260011720A (ko) | 항체-약물 접합체를 포함하는 약제 조성물 | |
| KR20240024941A (ko) | 항-pd1 항체의 제제 | |
| WO2022142053A1 (en) | Formulations of anti-cd73 antibodies | |
| US20240382411A1 (en) | Composition comprising pd-l1 antigen-binding fragment and use thereof | |
| EA052347B1 (ru) | Композиция, содержащая фрагмент, связывающий антиген pd-l1, и ее применение | |
| RU2789476C2 (ru) | Получение конъюгата антитело-лекарственное средство и его лиофилизация | |
| HK40103088A (en) | Anti-il5r antibody formulations | |
| RU2820576C2 (ru) | Стабильные составы антител против tigit, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| HK40077586A (en) | Anto-connexin antibody formulations | |
| KR20240108799A (ko) | 항 엽산 수용체 접합체 암 요법 | |
| KR20230053012A (ko) | 항-pd-1 항체를 포함하는 암의 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |